alpha 2 -delta site Inhibitors
1 drugsAbout alpha 2 -delta site
The alpha 2-delta (α2δ) site is an auxiliary subunit of voltage-gated calcium channels (VGCCs), modulating neuronal excitability and neurotransmitter release. Targeting this site can modulate calcium channel function, reducing neuronal hyperexcitability associated with various pain conditions.
The α2δ site is a pharmacological target for pain management, evidenced by one FDA-approved drug. Currently, there is no genetic evidence data available linking the α2δ site to specific diseases, representing an area for further research.
LYRICA (pregabalin) is the only FDA-approved drug targeting the α2δ site, indicated for 6 conditions and marketed by CP PHARMS. It is a small molecule, highlighting the potential for other modalities to be explored.
Top alpha 2 -delta site Drugs
CP PHARMS is the only company with an approved drug targeting this site.
The lack of competition suggests a high barrier to entry or an untapped market.
alpha 2 -delta site Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 2 -delta site, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
alpha 2 -delta site Clinical Trials 270 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on alpha 2 -delta site. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 44 | 40 | 0 | 4 | 100% |
| Phase 2 | 63 | 40 | 15 | 7 | 73% |
| Phase 3 | 66 | 51 | 12 | 3 | 81% |
| Phase 4 | 97 | 73 | 17 | 7 | 81% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved alpha 2 -delta site drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting alpha 2 -delta site. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
alpha 2 -delta site Drug Approval Timeline (2004 - 2004)
The first and only drug, LYRICA, was approved in 2004.
The approval timeline suggests a saturated market or a lack of innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 164 (45 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on alpha 2 -delta site. A trial counts if an approved drug acting on alpha 2 -delta site is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.